Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast
- 476 Downloads
Primary squamous cell carcinoma of the breast (PSCCB) is a rare type of breast carcinoma, the clinical behavior of which has not been accurately characterized. The aim of this study was to evaluate its prevalence, characteristics, prognosis, and effective treatment modalities in patients attending our institution. The records of the Cancer Institute and Hospital of Tianjin Medical University from 1985 to 2013 were searched and 29 patients with PSCCB (0.086 % of all patients with breast cancer) identified. Their clinicopathological features, treatment methods used, and outcomes were analyzed. The median tumor size was 4.50 cm. Axillary lymph nodes metastases were present in 41.4 % of patients. The median overall survival was 39 months (range 7–144 months), with 34.5 % surviving at 5 years. The median relapse-free survival was 32 months (range 4–144 months), with 27.6 % relapse-free surviving at 5 years. According to univariate analysis, the time interval between onset of the first symptom and first presentation to a health professional (TI) (P = 0.017), use of adjuvant chemotherapy (P = 0.044), and T stage (P = 0.048, T1 vs. T2, T3, T4) were significant prognostic factors for overall survival. PSCCB is an extremely aggressive disease associated with large tumor size, rapid progression, frequent relapse, and a high death rate. Imaging findings are nonspecific and easily misinterpreted as benign. Cisplatin-based chemotherapy may be effective. Early diagnosis and treatment of this rare entity are critical to patient prognosis.
KeywordsPrimary squamous cell carcinoma Breast cancer Characteristics Prognosis Therapeutic strategies
This study was supported by the National Natural Science Foundation of China (Grant No. 81201725) and the Foundation of Tianjin Medical University Cancer Institute and Hospital (Grant No. 1310).
Conflict of interest
None of the authors has any competing interests to declare. The authors have no relevant financial interests to disclose.
- 7.Honda M, Saji S, Horiguchi S, Suzuki E, Aruga T, Horiguchi K, Kitagawa D, Sekine S, Funata N, Toi M, Kuroi K (2011) Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast. Surg Today 41(3):328–332. doi: 10.1007/s00595-009-4276-2 PubMedCrossRefGoogle Scholar
- 9.Troell A (1908) Zwei Falle von Palttenepithelcarcinom. Nord Med Ark 1:1–11Google Scholar
- 10.Rosen PP (2009) Breast pathology. In: Rosen PP (ed) Rosen’s breast pathology, 3rd edn. Lippincott Williams and Wilkins, PhiladelphiaGoogle Scholar
- 16.Song Y, Liu X, Zhang G, Song H, Ren Y, He X, Wang Y, Zhang J, Zhang Y, Sun S, Liang X, Sun Q, Pang D (2013) Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol 11:129. doi: 10.1186/1477-7819-11-129 PubMedCentralPubMedCrossRefGoogle Scholar
- 18.Hiramatsu K, Kato K, Hirata A, Matsuba H, Hara T, Ito T, Miyata T, Akagawa T, Kutsuna Y, Machiki Y, Fujioka S (2007) A resected case of squamous cell carcinoma of the breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases. Gan To Kagaku Ryoho 34(3):443–446PubMedGoogle Scholar
- 20.Kashiwagi S, Okuno T, Ishihara S, Ishii M, Asano Y, Watanabe M, Morisaki T, Aomatsu N, Noda S, Kawajiri H, Nakano T, Kawakami N, Mitsukawa Y, Takashima T, Onoda N, Ishikawa T, Hirakawa K (2013) Effectiveness of eribulin chemotherapy for squamous cell carcinoma of the breast. Gan To Kagaku Ryoho 40(12):2369–2371PubMedGoogle Scholar